Analytical Data
-
Gene name
SPANXC
- Application
-
Alternative Names
CTp11; CT11.3; Cancer/Testis Antigen Family 11, Member 3; Cancer/testis-associated protein CTp11; Nuclear-associated protein SPAN-Xc; SPANX family member C
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NY87
-
Expression Region
Met1~Lys97
-
Molecular Weight
19kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPANXC is a member of the cancer/testis (CT) antigen family, which is typically expressed in human germ cells and various malignancies but not in normal somatic tissues. Recent studies have focused on the role of SPANXC in tumor immunology due to its potential as a target for cancer immunotherapy. Research has indicated that SPANXC is involved in the regulation of immune responses, particularly in the context of tumor development, making it a promising candidate for therapeutic intervention. Additionally, SPANXC’s expression in certain cancers, including melanoma and breast cancer, highlights its relevance in oncogenesis and the body’s immune evasion mechanisms. The exploration of SPANXC and its recombinant proteins offers insights into the design of personalized cancer vaccines and targeted therapies, aiming to harness the immune system to eradicate tumors while minimizing effects on healthy tissues. As the understanding of SPANXC’s biological functions deepens, it opens avenues for innovative research aimed at enhancing patient outcomes through novel immunotherapeutic strategies. Overall, SPANXC represents a significant focal point in the development of next-generation cancer treatments leveraging the body’s immune potential.
